Subclinical inflammation, C-reactive protein & cardiovascular risk

Indian Journal of Medical Research

Volumn 125, Issue 4, 2007, Pages 502-504

  Heald, A H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 BIS(PHOSPHOCHOLINE)HEXANE; ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINE DERIVATIVE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LEPTIN; LIPID; PENTRAXIN; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AFFINITY CHROMATOGRAPHY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 1Q; CORONARY ARTERY DISEASE; GENE LOCUS; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PATHOGENESIS; PROTEIN SECRETION; RISK ASSESSMENT; RISK REDUCTION; SATIETY; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR DISEASE; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 34547106559     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Tillett WS, Francis T. Serologic reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-71.
2. Lofstrom G. Nonspecific capsular swelling in pneumococci. Acta Med Scand 1943; 141: (Suppl): 7-97.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
4. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
5. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-62.
6. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
7. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
8. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77.
9. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 12: 425-32.
10. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
11. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
12. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-21.
13. Vikram NK, Misra A, Pandey RM, Dwivedi M, Luthra K, Dhingra V, et al. Association between subclinical inflammation & fasting insulin in urban young adult north Indian males. Indian J Med Res 2006; 124: 677-82.